Wu Larry, Salti Giovanni
iCare Medical Centre, Singapore.
Istituto Medlight, Firenze, Italy.
J Cosmet Dermatol. 2025 Jan;24(1):e16583. doi: 10.1111/jocd.16583. Epub 2024 Sep 25.
Excess skin laxity over the upper face can contribute to aging over the mid and lower face. We describe an innovative nonsurgical technique of facial rejuvenation by injecting Lanluma V over the scalp's vertex and parietal regions. Lanluma V is a poly-l-lactic acid (PLLA)-based collagen stimulator which contains 210 mg of PLLA, distributed by Sinclair Pharmaceutical. Lanluma V works by stimulating collagen regeneration to provide support for the treated area.
A retrospective review of 12 consecutive patients treated with Lanluma V over the vertex and parietal regions of the scalp to achieve nonsurgical rejuvenation of the upper, middle, and lower thirds of the face was conducted. The patients were treated over two sessions, 1 month apart. The treated patients were reviewed by a plastic surgeon and rated under the Global Aesthetic Improvement Scale (GAIS) 6 months after treatment.
The patients achieved an overall average of 1.16 grade improvement in GAIS. The average follow-up period is 6 months following completion of treatment. There was no reported incidence of non-scarring alopecia, which has been reported in the use of other, more viscous fillers such as calcium hydroxyapatite or high G' hyaluronic acid.
This innovative method of combined forehead and temporal lifting with Lanluma V allows for an average 1.16 grade improvement in GAIS. There is no reported incidence of non-scarring alopecia, which has been associated with other fillers.
上脸皮肤过度松弛会导致中脸和下脸衰老。我们描述了一种创新的非手术面部年轻化技术,即通过在头皮顶点和顶叶区域注射Lanluma V。Lanluma V是一种基于聚左旋乳酸(PLLA)的胶原蛋白刺激剂,含有210毫克PLLA,由辛克莱制药公司经销。Lanluma V通过刺激胶原蛋白再生为治疗区域提供支撑。
对12例连续患者进行回顾性研究,这些患者在头皮顶点和顶叶区域接受Lanluma V治疗,以实现面部上、中、下三分之一的非手术年轻化。患者分两个疗程治疗,间隔1个月。治疗后6个月,由整形外科医生对接受治疗的患者进行评估,并根据全球美学改善量表(GAIS)进行评分。
患者在GAIS上的总体平均改善等级为1.16级。平均随访期为治疗结束后6个月。未报告非瘢痕性脱发的发生率,而在使用其他更粘稠的填充剂(如羟基磷灰石或高G'透明质酸)时曾有过相关报告。
这种使用Lanluma V联合额部和颞部提升的创新方法可使GAIS平均提高1.16级。未报告与其他填充剂相关的非瘢痕性脱发的发生率。